OIA Welcomes New Strategic Investor Mark Stevenson, & New Board Advisor, Abel Archundia, to Drive Growth & Innovation in AI-Powered Precision Medicine
We are excited to announce the addition of two new supporters and collaborators of the OIA team, each of whom brings a wealth of expertise and a track record of success in their respective fields. Both are colleagues of OIA’s Founder, Dr. Hector Zenil, as CDL mentors at the Saïd Business School, University of Oxford.
We are pleased to introduce Mark Stevenson as our new smart investor, leading our Enterprise Investment Scheme (EIS) funding round. Mark has over 30 years of experience as a senior executive at the forefront of the Life Sciences industry.
Most recently, Mark served as the Executive Vice President and Chief Operating Officer of Thermo Fisher Scientific, a Fortune 100 global company with over $40 billion in sales. Mark has a proven track record of growing life sciences businesses by optimising strategy, innovation, and operations in complex, global business environments. He has executed large and small-scale M&A transactions and integrations and has led transformation initiatives to adapt to changing market conditions.
Healthcare systems worldwide are under immense pressure to improve the quality of care and outcomes for patients. It is clear artificial intelligence (AI) has the potential to work alongside clinicians and healthcare practitioners to shift to more personalised, precision medicine.
Inspired by Oxford Immune Algorithmics mission and expertise to apply super-human-like Artificial General Intelligence (AGI) to tackle disease and bring decentralised, precise and personalised medicine to everyone. Oxford Immune Algorithmics’s flagship product is a cutting-edge AI-driven solution to monitor people’s health that includes minimally invasive intelligent blood testing and lifestyle data collection.
Mark Stevenson, new OIA investor
We are also honoured to have Abel Archundia join us as a board advisor.
Abel is the former Head of Digital Transformation and IT for Bayer Pharmaceuticals and has been a member of Bayer's Digital Transformation Board and IT Board. Before that, he was the Global Head of Novartis TechOps/QA IT and Sandoz Division IT at Novartis. Abel's experience extends to supply chain management for Dell and serving as General Manager on the vendor side.
As a Chief Information Officer, Abel has extensive experience in large-scale transformation efforts, including post-merger integrations, IT transformation, and process governance.
Technology is dramatically changing the delivery of healthcare. This is critical if the technology is to be accepted by healthcare professionals, who must have confidence the technology is built to the right standards, certified by the relevant authorities, and based on peer-reviewed scientific research.
As we embark on this new chapter, we are confident that the combined expertise of our new collaborators, along with the continued visionary leadership of Dr. Zenil and the unwavering dedication of our team, will propel OIA to new heights in the field of AI-powered precision medicine.
“We are excited to be working with Mark and Abel as we are now at the stage where the technology is mature and we are ready to engage with customers around the world. Thanks to the expertise and commitment of our team, we have been able to develop and test our platform, Algocyte, in clinical settings to give us confidence we are ready for the next stage. Mark and Abel will be able to provide invaluable advice as we look to progress the business in the next few years.”
Dr. Hector Zenil; Founder, Director and Chief Visionary Officer
Our team's hard work, dedication, and contributions have been instrumental to OIA's success to date. Our cross-disciplinary team comprises AI experts, medical leaders, and IoT and optical engineering pioneers working at the forefront of science and technology. With our multidisciplinary approach, we can tackle some of the most pressing human health challenges, such as infection, cancer, antibiotic resistance, and tropical diseases, from a technological and commercial-viability point of view. We are passionate about using science and computational intelligence to push the boundaries of medical understanding and diagnostics. We aim to become a trusted provider of responsible and clinically validated tools to improve healthcare worldwide for early diagnosis, better disease treatment, and equal access to the best medical advice.